...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Liquidity
KBC, yes Don was referring to Zeniths lawyer in particular and I also think Don will figure out what makes the most sense for a Zenith IPO. I for one am glad that Zenith has been able to move through the biotech slide and latest market turbulence as a private company and I hope Zenith does not IPO until the markets have settled and Zenith newco can start off publicly closer to the bottom of a cycle. JMO
Share
New Message
Please login to post a reply